FMS Like Tyrosine kinase 3 Inhibitors Market Forecast to 2030
The most recent market research report from Emergen Research, titled Global FMS Like Tyrosine kinase 3 inhibitors Market, provides an estimated market size and share as well as current industry trends, global market growth rates, significant drivers and opportunities, difficulties, product segmentation, and key market competitors. Pricing range, size of the market, degree of competition, product offerings and details, and business histories
The global FMS-Like Tyrosine kinase 3 (FLT3) inhibitors market size was USD 405.6 Million in 2021 and is expected to register a revenue CAGR of 14.6% during the forecast period, according to the latest analysis by Emergen Research. Rising high-value investments for Research and Development (R&D) initiatives by various major pharmaceutical companies for improvement in therapy tolerability and drugs is a key factor driving market revenue growth. In addition, rising incidences of Acute Myeloid Leukemia (AML) and relapse cases, a growing number of potential pipeline drugs, and increasing approvals of new FLT3 inhibitor drugs by regulatory bodies are driving the revenue growth of the FLT3 inhibitors market.
According to Novartis, AML accounts for approximately 25% of all adult leukemias and has the lowest survival rate. FDA has now authorized three FLT3 inhibitors for use in the U.S. Midostaurin is approved for first-line treatment with chemotherapy, but gilteritinib is approved for R/R disease. Quizartinib and crenolanib are two new AML inhibitors in late-stage development for first-line and R/R treatments. Various advantages of improved targeted medicines, such as increased long-term survival rates, quality, and safety, are driving the growth of the FLT3 inhibitors market. According to Cancer.net, the 5-year survival rate for individuals aged 20 years and older with AML is 27%, whereas it is 69% for individuals younger than 20. In addition, the prognosis and survival of AML patients are strongly dependent on their mutation profile and age. Lower survival rates are due to the aging patient population's unfavorable mutation profile mixed with their inability to tolerate intense therapy. Moreover, the availability of medications with effectiveness and minimal toxicity, as well as oral formulations, is driving demand for FLT3 inhibitors, specifically among elderly and weak patients. On November 4, 2021, the Menarini Group received FDA Orphan Drug Designation (ODD) for SEL24/MEN1703 for the treatment of AML. SEL24/MEN1703 is a first-in-class, orally accessible, dual PIM/FLT3 inhibitor that Menarini in-licensed from Ryvu Therapeutics and is now being studied as a single drug in the DIAMOND-01 study for the treatment of patients with relapsed or refractory AML.
Request a Sample Report with Table of Contents and Figures to visit this site @ https://www.emergenresearch.com/request-sample/1302
The global FMS Like Tyrosine kinase 3 Inhibitors market report employs an extremely extensive and perceptive process that analyzes statistical data relating to services and products offered in the market. The research study is a pivotal document in understanding the needs and wants of the clients. The report is comprised of significant data about the leading companies and their marketing strategies. The FMS Like Tyrosine kinase 3 Inhibitors industry is witnessing an expansion and change of dynamics owing to the entry of several new players.
The study outlines the rapidly evolving and growing market segments along with valuable insights into each element of the industry. The industry has witnessed the entry of several new players, and the report aims to deliver insightful information about their transition and growth in the market. Mergers, acquisitions, partnerships, agreements, product launches, and joint ventures are all outlined in the report.
Astellas Pharma Inc., Novartis AG, Pfizer Inc., Daiichi Sanyo Company, Limited, Cullinan Oncology, Inc., AROG Pharmaceuticals, Inc., Aptose Biosciences Inc., FUJIFILM Pharmaceuticals U.S.A., Inc., CSPC Pharmaceutical Group Limited, and Allarity Therapeutics, Inc
Click to access the Report Study, Read key highlights of the Report and Look at Projected Trends @ https://www.emergenresearch.com/industry-report/fms-like-tyrosine-kinase-3-inhibitors-market
Some Key Highlights From the Report
The gilteritinib segment accounted for largest revenue share in 2021 owing to continuing clinical trials and increasing regulatory approvals. Gilteritinib, which is a kinase inhibitor, is recommended for people with acute myeloid leukemia that has relapsed or become resistant to treatment and has FLT3-TKD or FLT3-ITD mutation. This can increase patients survival rates, which is one of the main requirements for getting regulatory approval. For patients with severe, relapsing, or refractory illness, gilteritinib is a safe, mutation-targeted therapeutic option. A complex pyrazine carboxamide derivative, medication also has increased activity, selectivity, and effectiveness against FLT3-TKD and FLT3-ITD mutations.
Type 1 FLT3 inhibitors segment accounted for largest revenue share in 2021 owing to increasing number of successful clinical trials and research studies. Type 1 inhibitors are more effective in AML cells containing either ITD or TKD mutations as they inhibit ATP binding in contrast to Type 2 FLT3 inhibitors. Moreover, Type 1 FLT3 inhibitors can be used in patients who have relapsed owing to acquired TKD mutations, which is one of the key factors driving revenue growth of the market. Type 1 inhibitors include midostaurin, crenolanib, and gilteritinib. Additionally, better efficacy, fewer side effects, and low toxicity of drugs are major factors driving revenue growth of this segment.
The North America market accounted for largest revenue share in 2021. A few factors driving market revenue growth include surging number of AML patients, rising requirement for targeted therapies as well as increasing investments by major pharmaceutical companies for R&D in the area of FLT3 inhibitors drug development. Furthermore, rising collaborations between governments and pharmaceutical companies and increasing number of approval of new innovative drugs along with a number of potential pipeline drugs are significantly contributing to growth of the FLT3 inhibitors market in North America.
Market Overview:
The report bifurcates the FMS Like Tyrosine kinase 3 Inhibitors market on the basis of different product types, applications, end-user industries, and key regions of the world where the market has already established its presence. The report accurately offers insights into the supply-demand ratio and production and consumption volume of each segment.
Segments Covered in this report are:
Drug Type Outlook (Revenue, USD Million; 2019-2030)
Midostaurin
Gilteritinib
Sorafenib
Therapies Outlook (Revenue, USD Million; 2019-2030)
Type 1 FLT3 inhibitors
Type 2 FLT3 inhibitors
Regional Outlook (Revenue, USD Million; 2019–2030)
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Benelux
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Rest of APAC
Latin America
Brazil
Rest of LATAM
Middle East & Africa
Saudi Arabia
UAE
South Africa
Turkey
Rest of Middle East & Africa
Request a impresive discount on the report, click on here @ https://www.emergenresearch.com/request-discount/1302
The research report offers a comprehensive regional analysis of the market with regards to production and consumption patterns, import/export, market size and share in terms of volume and value, supply and demand dynamics, and presence of prominent players in each market.
Regional Analysis Covers:
North America (U.S., Canada)
Europe (U.K., Italy, Germany, France, Rest of EU)
Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
Latin America (Chile, Brazil, Argentina, Rest of Latin America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
Furthermore, the report provides the analytical data in an organized format segmented into charts, tables, graphs, figures, and diagrams. This enables readers to understand the market scenario in an easy and beneficial manner. Moreover, the report aims to impart a prospective outlook and draw an informative conclusion to assist the reader in making lucrative business decisions. The report, in conclusion, provides a detailed analysis of the segments expected to dominate the market, the regional bifurcation, the estimated market size and share, and comprehensive SWOT analysis and Porter’s Five Forces Analysis.
Request customization of the report @ https://www.emergenresearch.com/request-history/1302
Thank you for reading our report. For further queries, please connect with us, and our team will provide you the report best suited to your requirements.
Latest Reports Published by Emergen Research:
flying car market
https://www.emergenresearch.com/industry-report/flying-car-market
automotive navigation systems market
https://www.emergenresearch.com/industry-report/automotive-navigation-systems-market
long read sequencing market
https://www.emergenresearch.com/industry-report/long-read-sequencing-market
multichannel campaign management market
https://www.emergenresearch.com/industry-report/multichannel-campaign-management-market
lead free piezoelectric ceramic material market
https://www.emergenresearch.com/industry-report/lead-free-piezoelectric-ceramic-material-market
machine safety market
https://www.emergenresearch.com/industry-report/machine-safety-market
orthopedics diagnostic devices market
https://www.emergenresearch.com/industry-report/orthopedics-diagnostic-devices-market
Exosomes Market
https://www.emergenresearch.com/industry-report/exosomes-market
Digital Printing Market
https://www.emergenresearch.com/industry-report/digital-printing-market
Biometric System Market
https://www.emergenresearch.com/industry-report/biometric-system-market
About Us:
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights
Explore Our Custom Intelligence services | Growth Consulting Services
Latest Report: heart rhythm devices market, cancer tumor profiling market
Trending Title: pharmacogenomics market, Cell-Free DNA Testing Market